The 7 most recent market catalysts affecting $VTGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety Disorder
Vistagen announced positive exploratory data for its lead drug candidate, fasedienol nasal spray, at a medical conference. This data, while exploratory and from subpopulation analy…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Vistagen shares are trading higher after the company announced preliminary data from the open-label extension portion of its PALISADE-4 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder.
This headline represents a significant corporate catalyst for Vistagen. Positive preliminary data from a Phase 3 clinical trial, especially for an open-label extension, indicates a…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
Vistagen Says Fasedienol Well-Tolerated Up To 12 Months In Preliminary Open-Label Extension Of Phase 3 Social Anxiety Trial; Plans FDA Meeting This Quarter On New Phase 3
The positive safety data for Fasedienol, particularly over an extended 12-month period in an open-label extension, is a critical de-risking event for Vistagen. Safety is paramount …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
Vistagen Says Exploratory Phase 2 Repeat Dose Study Of Fasedienol Missed Statistical Significance On Primary Endpoint (p=0.2); Reports Nominal Significance In Very Severe Social Anxiety Subgroup
The missed statistical significance on the primary endpoint for Fasedienol is a major blow for Vistagen, as it significantly reduces the likelihood of the drug progressing through …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Vistagen Therapeutics shares are trading higher after SRX Global announced that it has acquired a stake in the company.
This headline represents a significant corporate catalyst for Vistagen Therapeutics. The acquisition of a stake by SRX Global indicates a vote of confidence in Vistagen's pipeline …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
SRX Global Acquires Stake In Vistagen Therapeutics; Deal Terms Were Undisclosed
SRX Global has disclosed an acquisition of a stake in Vistagen Therapeutics, viewing the shares as undervalued. This signals potential activist investor involvement, as SRX Global …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.